Prelude Therapeutics Inc cotiza a 3.74 USD y tiene una capitalización bursátil de $298M. En los últimos 12 meses ha facturado $22M con un margen de flujo de caja libre del -464.3%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia …
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | — | $-0.13 | $-0.20 |
| Estimado | $-0.15 | $-0.18 | $-0.27 | $-0.18 |
| Sorpresa | — | — | +51.9% | -11.1% |
| Métrica | PRLD | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -861.3% | -38.6% | -822.7% |
| Net Margin | -819.6% | -33.6% | -786.0% |
| FCF Margin | -464.3% | -13.9% | -450.5% |
| ROE | -145.0% | -40.4% | -104.6% |
| ROA | -70.4% | -32.0% | -38.4% |
| Current Ratio | 1.99 | 2.84 | -0.85 |
| Debt / Equity | — | 0.28 | — |